Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Haas

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Clinical Neurology and Neurosurgery|September 13, 2020
Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in GermanySebastian Rauer, Muna-Miriam Hoshi, Refik Pul, et al.
The Lancet Regional Health. Europe|September 12, 2022
SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational studyNiklas Frahm, Firas Fneish, David Ellenberger, et al.
Clinical Therapeutics|June 11, 2004
A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosisJ Theodore Phillips, George Rice, Elliot Frohman, et al.
BMC Neurology|January 20, 2017
Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring studyVolker Limmroth, Tjalf Ziemssen, Michael Lang, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 29, 2012
Anti-JC-virus antibody prevalence in a German MS cohortClemens Warnke, Thomas Dehmel, Anita Posevitz-Fejfár, et al.
Archives of Neurology|June 16, 2005
Hematopoietic stem cell transplantation for multiple sclerosisRichard K Burt, Bruce Cohen, John Rose, et al.
BMJ Open|January 26, 2022
Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocolHeidrun Golla, Kim Dillen, Martin Hellmich, et al.
Arthritis Research & Therapy|May 17, 2011
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)Hans-Peter Tony, Gerd Burmester, Hendrik Schulze-Koops, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Clinical Neurology and Neurosurgery|September 13, 2020
Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in GermanySebastian Rauer, Muna-Miriam Hoshi, Refik Pul, et al.
The Lancet Regional Health. Europe|September 12, 2022
SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational studyNiklas Frahm, Firas Fneish, David Ellenberger, et al.
Clinical Therapeutics|June 11, 2004
A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosisJ Theodore Phillips, George Rice, Elliot Frohman, et al.
BMC Neurology|January 20, 2017
Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring studyVolker Limmroth, Tjalf Ziemssen, Michael Lang, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 29, 2012
Anti-JC-virus antibody prevalence in a German MS cohortClemens Warnke, Thomas Dehmel, Anita Posevitz-Fejfár, et al.
Archives of Neurology|June 16, 2005
Hematopoietic stem cell transplantation for multiple sclerosisRichard K Burt, Bruce Cohen, John Rose, et al.
BMJ Open|January 26, 2022
Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocolHeidrun Golla, Kim Dillen, Martin Hellmich, et al.
Arthritis Research & Therapy|May 17, 2011
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)Hans-Peter Tony, Gerd Burmester, Hendrik Schulze-Koops, et al.
Pageof 5